Sugi Predict

Sugi Predict / Targets / SIRT2

SIRT2

NAD-dependent protein deacetylase sirtuin-2 · Q8IXJ6 · SIRT2 on Sugi Atlas →

106,294 patent compounds predicted against SIRT2, 54,529 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL328657 SCHEMBL328657 0.56 13/20
SCHEMBL236067 SCHEMBL236067 0.51 13/20
SCHEMBL209612 SCHEMBL209612 0.71 10/20
SCHEMBL150166 SCHEMBL150166 0.69 10/20
SCHEMBL130760 SCHEMBL130760 0.47 10/20
SCHEMBL203978 SCHEMBL203978 0.53 9/20
SCHEMBL250411 SCHEMBL250411 0.54 8/20
SCHEMBL133032 SCHEMBL133032 0.53 8/20
SCHEMBL254960 SCHEMBL254960 0.53 8/20
SCHEMBL57020 SCHEMBL57020 0.48 8/20
SCHEMBL293103 SCHEMBL293103 0.45 8/20
SCHEMBL203965 SCHEMBL203965 0.61 7/20
SCHEMBL330276 SCHEMBL330276 0.52 7/20
SCHEMBL133395 SCHEMBL133395 0.49 7/20
SCHEMBL47273 SCHEMBL47273 0.55 6/20
SCHEMBL213832 SCHEMBL213832 0.54 6/20
SCHEMBL175535 SCHEMBL175535 0.53 6/20
SCHEMBL203702 SCHEMBL203702 0.50 6/20
SCHEMBL173853 SCHEMBL173853 0.49 6/20
SCHEMBL254236 SCHEMBL254236 0.48 6/20

Clinical trials — most relevant to SIRT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient PHASE4UNKNOWN
Cardiotoxicity in Breast Cancer Patients PHASE4RECRUITING
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC). PHASE4COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Impact of P53 and SIRT1 in Type 2 Diabetes PHASE3RECRUITING
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age PHASE2COMPLETED
Oral Nitrite for Older Heart Failure Patients PHASE2COMPLETED
The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care PHASE2COMPLETED
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals PHASE2RECRUITING
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma PHASE2COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors PHASE1RECRUITING
Project SIRT6 Activator nanRECRUITING
Sirtuin1 in COVID19 Patients nanUNKNOWN
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery nanNOT_YET_RECRUITING
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
How Sirtuin Levels Change During Behçet Disease nanUNKNOWN
SWE to Detect Enthesitis in PsA: Relationship With SIRT2 Expression and Disease Activity nanNOT_YET_RECRUITING
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis nanUNKNOWN
Comparison of Cardiometabolic Markers in Individuals With Hypertriglyceridemia With Low and High Weight Loss Responses to an Energy-restricted Diet nanCOMPLETED
Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS nanCOMPLETED
Short Interval Resveratrol Trial in Cardiovascular Surgery nanACTIVE_NOT_RECRUITING
Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects nanCOMPLETED
Inflammation in COPD and the Effect of Nicotinamide Riboside nanCOMPLETED
Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients. nanCOMPLETED
Inflammatory Axis and Sirtuins' in Overweight Pre-diabetics Patients nanCOMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults nanUNKNOWN
Nutritional Intervention-induced Weight Loss During the Oncological Treatment of Obesity-related Breast Cancer nanUNKNOWN
Nicotinamide Riboside Clinical Trial for GWI nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a SIRT2 binder may also engage these)

ProteinNameSimilarity
Q4R834 — 1.000 Q4R834 →
Q8VDQ8 — 0.995 Q8VDQ8 →
Q5RBF1 — 0.994 Q5RBF1 →
Q5RJQ4 — 0.990 Q5RJQ4 →
Q9I7I7 — 0.988 Q9I7I7 →
Q7ZVK3 — 0.985 Q7ZVK3 →
Q8R104 — 0.982 Q8R104 →
Q8BKJ9 — 0.982 Q8BKJ9 →
Q0P595 — 0.982 Q0P595 →
Q5AW69 — 0.981 Q5AW69 →
A7Z050 — 0.981 A7Z050 →
Q9Y4B4 — 0.980 Q9Y4B4 →
Q5RDF1 — 0.980 Q5RDF1 →
Q7XWV4 — 0.980 Q7XWV4 →
Q8C0D5 — 0.980 Q8C0D5 →
Q7ZU90 — 0.980 Q7ZU90 →
Q3SYT1 — 0.980 Q3SYT1 →
Q6PFW1 — 0.980 Q6PFW1 →
Q14147 — 0.980 Q14147 →
B8ARK7 — 0.979 B8ARK7 →
Q8MJ26 — 0.979 Q8MJ26 →
Q68FX9 — 0.979 Q68FX9 →
B2RZ55 — 0.979 B2RZ55 →
Q9CXF7 — 0.979 Q9CXF7 →
Q9D2E2 — 0.979 Q9D2E2 →
Q5R6G3 — 0.979 Q5R6G3 →
Q25337 — 0.979 Q25337 →
Q8HY87 — 0.979 Q8HY87 →
Q6P1R4 — 0.979 Q6P1R4 →
GAK Cyclin-G-associated kinase 0.979 landscape →